ReviewScience progress
Therapeutic plasma exchange in hypertriglyceridemia-induced acute pancreatitis: A narrative review of indications, timing, and clinical outcomes.
Review in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertriglyceridemia (HTG) is the third leading cause of acute pancreatitis (AP) and is associated with considerable morbidity and mortality. Rapid triglyceride (TG) reduction is a central component of treatment for hypertriglyceridemia-induced acute pancreatitis (HTG-AP). Therapeutic plasma exchange (TPE) has been increasingly applied in HTG-AP, and recent studies have further evaluated its clinical value. This narrative review adheres to the Scale for the Assessment of Narrative Review Articles (SANRA). Relevant databases were searched to identify eligible randomized controlled trials, retrospective studies, case series and clinical guidelines regarding HTG-AP management. This analysis indicates that TPE can rapidly lower plasma TG levels and may be most useful in severe HTG-AP patients with organ dysfunction and markedly elevated TG levels. However, the available evidence is mainly retrospective and heterogeneous. Its effect on hard clinical outcomes, optimal timing, patient selection, and treatment protocols therefore remain uncertain. Further high-quality studies are needed to standardize TPE protocols and confirm its clinical benefits. This review summarizes current evidence to help clinicians optimize the use of TPE in the management of HTG-AP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.